Estimated impact on disability-adjusted life years (DALYs) of GLP1-RA or SGLT2-i treatment among people with diabetes taking insulin across treatment scenarios, showing overall among all countries regardless of sample size, and the subset of countries with N > 100 people with diabetes reporting insulin use. This evidence concerns the gene SLC5A2 and diabetes mellitus.